Shenkangding Jiaonang for treating chronic nephrosis

Abstract

The invention discloses Shenkangding Jiaonang for treating chronic nephrosis. The Shenkangding Jiaonang is prepared from the following raw materials in part by weight: 27 to 33 parts of sculellaria barbata, 27 to 33 parts of winged euonymus twig, 27 to 33 parts of oldenlandia diffusa, 8 to 12 parts of paniculate swallowwort root, 13 to 17 parts of alisma plantagoaquatica, 13 to 17 parts of fried atractylodes lancea, 27 to 33 parts of lightyellow sophora root, 8 to 12 parts of honeysuckle, 8 to 12 parts of hiraute shiny bugleweed herb, 17 to 23 parts of root of red-rooted salvia, 13 to 17 parts of Chinese pyrola herb, 22 to 28 parts of hairyvein agrimonia herb and bud, 11 to 14 parts of root of rehmannia, 13 to 17 parts of fried bighead atractylodes rhizome, 8 to 12 parts of eucommia bark, and 8 to 12 parts of safflower. The invention has the advantages of eliminating the pathogenic factor and eliminating body resistance by strengthening the spleen, tonifying kidney and qi, nourishing yin, activating blood circulation, promoting dieresis, detoxifying and removing stasis. Meanwhile, Shenkangding Jiaonang can reduce proteinuria and hematuresis and can improve kidney functions. The Shenkangding Jiaonang also has the characteristics of good treatment effect, readily available material, simple preparation process, low preparation cost, low price that can be afforded by ordinary people, safety, no toxic or side effects, and convenient administration.

Description

technical field [0001] The invention relates to a medicine made of Chinese herbal medicine, in particular to a Shenkangding capsule for treating chronic kidney disease. Background technique [0002] Kidney disease is a common disease, frequently-occurring disease. According to relevant survey statistics in my country, about 150 to 300 people per million people become disabled or die due to renal failure every year. Although there are no accurate statistics at present, experts estimate that there are about several million chronic renal failure (hereinafter referred to as CRF) patients in the whole country. In recent years, the number of CRF cases in this area has increased significantly. The most common cause of CRF is chronic nephritis, which accounts for 60% of the number of dialysis patients. Uremic patients need long-term hemodialysis to survive. Although it can prolong life, it is a non-physiological therapy that will bring many side effects and the quality of life is ...

AI Technical Summary

Problems solved by technology

Patients with uremia need long-term hemodialysis to survive. Although it can prolong life, it is a non-physiological therapy that will bring many side effects and the quality of life is not high

Kidney transplantation is the direction of development, but the 5-10-year survival rate is not too high at this stage, and transplant recipients still need to take expensive anti-rejection drugs, causing a heavy economic burden on the family and society

How to prevent chronic nephritis from developing to renal insufficiency is currently a hot spot in nephrology research. The unsatisfactory curative effect of traditional treatment and the limitations of expensive medicines prevent many early nephritis from being treated in time